IN2014DN03277A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN03277A IN2014DN03277A IN3277DEN2014A IN2014DN03277A IN 2014DN03277 A IN2014DN03277 A IN 2014DN03277A IN 3277DEN2014 A IN3277DEN2014 A IN 3277DEN2014A IN 2014DN03277 A IN2014DN03277 A IN 2014DN03277A
- Authority
- IN
- India
- Prior art keywords
- crystal
- hydrochloride
- compound
- crystals
- formula
- Prior art date
Links
- 239000013078 crystal Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- 238000000354 decomposition reaction Methods 0.000 abstract 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 abstract 1
- 238000004321 preservation Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011246209 | 2011-11-10 | ||
| JP2012071739 | 2012-03-27 | ||
| PCT/JP2012/007195 WO2013069297A1 (ja) | 2011-11-10 | 2012-11-09 | ７－｛（３s、４s）－３－［（シクロプロピルアミノ)メチル］－４－フルオロピロリジン－1－イル｝－６－フルオロ－１－（２－フルオロエチル）－８－メトキシ－４－オキソ－１、４－ジヒドロキノリン－３－カルボン酸の結晶 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03277A true IN2014DN03277A (enExample) | 2015-05-22 |
Family
ID=48289529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3277DEN2014 IN2014DN03277A (enExample) | 2011-11-10 | 2012-11-09 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9090587B2 (enExample) |
| EP (2) | EP3112359B1 (enExample) |
| JP (4) | JP5871948B2 (enExample) |
| KR (2) | KR102162208B1 (enExample) |
| CN (2) | CN104945375B (enExample) |
| AU (1) | AU2016273899B2 (enExample) |
| BR (1) | BR112014010765B1 (enExample) |
| CA (1) | CA2855022C (enExample) |
| ES (2) | ES2621664T3 (enExample) |
| IN (1) | IN2014DN03277A (enExample) |
| MX (1) | MX375073B (enExample) |
| NZ (1) | NZ623808A (enExample) |
| RU (2) | RU2615509C2 (enExample) |
| SA (1) | SA112330992B1 (enExample) |
| SG (2) | SG10201608167UA (enExample) |
| TW (1) | TWI547492B (enExample) |
| WO (1) | WO2013069297A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12594418B2 (en) | 2011-03-10 | 2026-04-07 | Electrocore, Inc. | Devices and methods for nerve stimulation |
| SA112330992B1 (ar) * | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| CN105338982B (zh) | 2013-04-25 | 2017-10-10 | 杏林制药株式会社 | 固体药用组合物 |
| JP6349306B2 (ja) * | 2013-04-25 | 2018-06-27 | 杏林製薬株式会社 | 錠剤 |
| US9687453B2 (en) | 2013-04-25 | 2017-06-27 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| JP6018334B2 (ja) * | 2014-10-23 | 2016-11-02 | 杏林製薬株式会社 | 固形医薬組成物 |
| EP3210608A4 (en) * | 2014-10-23 | 2018-06-20 | Kyorin Pharmaceutical Co., Ltd. | Solid pharmaceutical composition |
| MX380385B (es) | 2015-03-13 | 2025-03-12 | Kyorin Seiyaku Kk | Agente para el tratamiento de infeccion respiratoria. |
| WO2016195020A1 (ja) * | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | 水性液剤 |
| JP6031217B1 (ja) | 2015-06-02 | 2016-11-24 | 杏林製薬株式会社 | 水性液剤 |
| WO2016195014A1 (ja) * | 2015-06-02 | 2016-12-08 | 杏林製薬株式会社 | 水性液剤 |
| MY200429A (en) | 2017-06-16 | 2023-12-26 | Kyorin Seiyaku Kk | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| CA3067188A1 (en) | 2017-06-16 | 2018-12-20 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent for aspiration pneumonia, lung suppuration, or lung abscess |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA944369B (en) * | 1993-08-27 | 1995-02-13 | Hokuriku Seuyaku Co Ltd | 5-amino-8-methyl-7-pyrrolidinylquinoline-3-carboxylic acid derivative |
| CN1158846A (zh) * | 1995-05-09 | 1997-09-10 | 昆山市康壮达兽药厂 | 盐酸氟哌酸的合成工艺 |
| WO2003014732A1 (en) | 2001-08-10 | 2003-02-20 | Symyx Technologies, Inc. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| AU2002236267A1 (en) * | 2002-03-08 | 2003-09-22 | Daiichi Pharmaceutical Co., Ltd. | Quinolonecarboxylic acid derivative |
| PL1666477T3 (pl) | 2003-09-10 | 2013-11-29 | Kyorin Seiyaku Kk | Pochodna kwasu 7-(4-podstawionego-3-cyklopropyloaminometylo-1- pirolidynylo)chinolonokarboksylowego |
| CN101003540A (zh) * | 2006-01-18 | 2007-07-25 | 广州白云山制药股份有限公司广州白云山制药总厂 | 一种抗感染化合物和用途 |
| SA112330992B1 (ar) * | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
-
2012
- 2012-11-07 SA SA112330992A patent/SA112330992B1/ar unknown
- 2012-11-09 ES ES12846895.6T patent/ES2621664T3/es active Active
- 2012-11-09 KR KR1020197015481A patent/KR102162208B1/ko active Active
- 2012-11-09 CN CN201510329284.3A patent/CN104945375B/zh active Active
- 2012-11-09 RU RU2014123567A patent/RU2615509C2/ru active
- 2012-11-09 SG SG10201608167UA patent/SG10201608167UA/en unknown
- 2012-11-09 EP EP16177827.9A patent/EP3112359B1/en not_active Not-in-force
- 2012-11-09 NZ NZ623808A patent/NZ623808A/en not_active IP Right Cessation
- 2012-11-09 JP JP2013542858A patent/JP5871948B2/ja active Active
- 2012-11-09 KR KR1020147012681A patent/KR20140098074A/ko not_active Ceased
- 2012-11-09 RU RU2017109814A patent/RU2017109814A/ru unknown
- 2012-11-09 US US14/352,141 patent/US9090587B2/en not_active Expired - Fee Related
- 2012-11-09 BR BR112014010765-3A patent/BR112014010765B1/pt not_active IP Right Cessation
- 2012-11-09 IN IN3277DEN2014 patent/IN2014DN03277A/en unknown
- 2012-11-09 CN CN201280055120.0A patent/CN103930414B/zh active Active
- 2012-11-09 EP EP12846895.6A patent/EP2778159B1/en not_active Not-in-force
- 2012-11-09 CA CA2855022A patent/CA2855022C/en not_active Expired - Fee Related
- 2012-11-09 SG SG11201401817TA patent/SG11201401817TA/en unknown
- 2012-11-09 ES ES16177827T patent/ES2747303T3/es active Active
- 2012-11-09 WO PCT/JP2012/007195 patent/WO2013069297A1/ja not_active Ceased
- 2012-11-09 TW TW101141841A patent/TWI547492B/zh active
- 2012-11-09 MX MX2017006000A patent/MX375073B/es unknown
-
2015
- 2015-06-17 US US14/741,713 patent/US9328089B2/en not_active Ceased
- 2015-08-25 JP JP2015165879A patent/JP6514069B2/ja active Active
-
2016
- 2016-12-14 AU AU2016273899A patent/AU2016273899B2/en not_active Ceased
-
2017
- 2017-05-08 JP JP2017092125A patent/JP6349435B2/ja active Active
-
2018
- 2018-05-02 US US15/969,342 patent/USRE47785E1/en not_active Expired - Fee Related
- 2018-07-13 JP JP2018132781A patent/JP6818719B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX375073B (es) | Cristal de acido 7-{(3s,4s)-3-[(ciclopropilamino)metil]-4-fluoropirrolidin-1-il}-6-fluoro-1-(fluoroetil)-8-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico. | |
| NZ734896A (en) | Novel 4-methoxy pyrrole derivatives or salts thereof and pharmaceutical composition comprising the same | |
| EA201490759A1 (ru) | Ингибиторы протеинкиназы | |
| PH12016500169A1 (en) | Polymorph of syk inhibitors | |
| CA2875877C (en) | Syk inhibitors | |
| SA515361086B1 (ar) | Fasn مركبات وتركيبات جديدة لتثبيط | |
| CR20140042A (es) | Indazoles | |
| CR20130333A (es) | Compuestos indol o análogos de los mismos útiles en el tratamiento de la degeneración macular relacionada con la edad (dmae) | |
| IN2014MN02106A (enExample) | ||
| PH12014501719A1 (en) | Pyridone derivatives | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| IN2014MN01897A (enExample) | ||
| AU2012313888A8 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | |
| WO2014028597A3 (en) | 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| JO3317B1 (ar) | مركبات تترا هيدروبيرولو ثيازين | |
| IN2014MN02459A (enExample) | ||
| MA39866A (fr) | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle | |
| EA201500930A1 (ru) | Новые ингибиторы | |
| MX359069B (es) | Sal y formas cristalinas de inhibidor de quinasa tipo polo-4. | |
| MX368178B (es) | Compuestos de ácido dimetilbenzoico. | |
| MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
| CY1118079T1 (el) | Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης | |
| PH12013501840A1 (en) | Nitrogen-containing saturated heterocyclic compound | |
| MY185971A (en) | Pyranodipyridine compound | |
| EA201390374A1 (ru) | Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина |